AbCellera (ABCL) Stock Jumps 32% After Menopause Drug Nails Phase 2

TLDR

• AbCellera stock jumped 32% to $9.12 after its menopause drug ABCL635 met primary endpoints in a Phase 2 trial
• A single 600mg dose of ABCL635 reduced hot flash frequency by 8.8 events per day versus 3.5 for placebo
• The drug also reduced symptom severity and improved sleep quality in trial participants
• The trial enrolled 92 postmenopausal women and was randomized, double-blind, and placebo-controlled
• No serious adverse events were reported during the four-week treatment period

AbCellera (ABCL) stock jumped 32% to $9.12 on Monday after its experimental menopause drug posted strong Phase 2 results.

AbCellera Biologics Inc., ABCL

The stock had already more than doubled in 2026 heading into Monday, driven largely by anticipation for this data readout.

ABCL635 is a non-hormonal, long-acting treatment given as a single subcutaneous injection. It targets the neurokinin 3 receptor, which plays a role in triggering hot flashes.

The Phase 2 trial enrolled 92 postmenopausal women who were experiencing around 10 moderate or severe hot flashes per day. Participants received either a single 600mg subcutaneous dose of ABCL635 or a placebo.

… Continue reading the full article at the original source below.